^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PD-L1 expression + MSI-H/dMMR

i
Entrez ID:
Related biomarkers:
11ms
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. (PubMed, BMC Med)
MSI-H status was associated with a higher TMB value and more positive PD-L1 expression in CCA tumors. Moreover, in patients with advanced CCA who received PD-1 inhibitor-based immunotherapy, MSI-H and positive PD-L1 expression were associated with improved both OS and PFS.
Journal • Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • KMT2D (Lysine Methyltransferase 2D) • RNF43 (Ring Finger Protein 43) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • ACVR2A (Activin A Receptor Type 2A)
|
PD-L1 expression • TMB-H • MSI-H/dMMR • ARID1A mutation • PBRM1 mutation • RNF43 mutation • PD-L1 expression + MSI-H/dMMR
1year
Proportion and distribution of PD-L1 expression and associated clinicopathologic features in patients with microsatellite instability-high gastric cancer. (ASCO-GI 2024)
In this study, the prevalence of MSI-H phenotype is approximately 8.5% of unselected GCs. Approximately 76% of patients with MSI-H tumors showed PD-L1 expression with at least 1 CPS, and 50% revealed PD-L1 expression with at least 10 CPS, who can respond better to immune checkpoint inhibitors with promising therapeutic benefits. Due to the peritumoral expression of immune cells in PD-L1 positive GCs with MSI-H phenotype, different endoscopic approaches to obtain tumor tissues for PD-L1 evaluation would be considered, such as sampling tissues at the tumor periphery.
Clinical • Microsatellite instability • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR • PD-L1 expression + MSI-H/dMMR
|
VENTANA PD-L1 (SP263) Assay
over1year
Micropapillary histology (MPUC) and extra-cellular domain ERBB2 (ERBB2 ECD+) mutations in urothelial bladder cancer (UBC) (ESMO 2023)
Background Given the early promising data with afatinib in advanced UC and the recent approval in NSCLC for anti-HER2 targeted therapy for activating kinase domain exon 20 ERBB2 insertion mutations, there is considerable interest in targeting additional locations in the ERBB2 gene in other tumor types...Conclusions ERBB2 ECD mutation-driven UBC represents a distinct subtype of UBC featuring an enrichment of MPUC histology from 1-2% to 28% incidence in ERBB2 ECD mutated UBC, and unique clinical and molecular characteristics, including differences in mutational signatures and genetic ancestry. Further exploration of anti-HER2 targeted therapy for non-amp sequence mutations in ERBB2 in UBC appears warranted.
Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • RB1 (RB Transcriptional Corepressor 1) • MTAP (Methylthioadenosine Phosphorylase) • KMT2D (Lysine Methyltransferase 2D)
|
PD-L1 expression • MSI-H/dMMR • PD-L1 overexpression • HER-2 amplification • HER-2 mutation • HER-2 S310F • HER-2 S310Y • HER-2 exon 20 mutation • HER-2 amplification + PD-L1 expression • PD-L1 expression + MSI-H/dMMR
|
PD-L1 IHC 22C3 pharmDx
|
Gilotrif (afatinib)
over1year
Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer. (PubMed, Cancer Sci)
Taken together, these results suggested that KMT2C/D LOF variants could be a useful predictor for ICIs efficacy in colorectal cancer. Meanwhile, the predictive value of KMT2C/D LOF variants was consistent with their association with TILs levels.
Journal • Checkpoint inhibition • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • KMT2D (Lysine Methyltransferase 2D) • KMT2C (Lysine Methyltransferase 2C)
|
PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • KMT2C mutation • PD-L1 expression + MSI-H/dMMR
2years
Molecular landscape and clinical implication of CCNE1-amplified esophagogastric cancer. (ASCO-GI 2023)
"While there were no differences in OS between CCNE1-amp vs non-amp GA, CCNE1Amp was associated with worse OS after trastuzumab in the IHC HER2+ cohort (N=9 vs 28; HR (95% CI): 2.95 (1.18 – 7.34), p = 0.015)...CCNE1Amp is associated with a distinct molecular profile in EGC and resistance to HER2-targeted therapy. While CCNE1-amp tumors are thought to be generally “immune-cold,”CCNE1-amp GA demonstrated potentially improved outcomes with immunotherapy. Further investigation of CCNE1Amp as a predictive biomarker is warranted, particularly as novel therapeutics selectively targeting CCNE1Amp are under clinical investigation."
Clinical
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCNE1 (Cyclin E1) • CDH1 (Cadherin 1)
|
PD-L1 expression • HER-2 positive • MSI-H/dMMR • HER-2 amplification • HER-2 mutation • CCNE1 amplification • CDKN2A mutation • HER-2 amplification + PD-L1 expression • CCNE1 expression • PD-L1 expression + MSI-H/dMMR
|
PD-L1 IHC 22C3 pharmDx
|
Herceptin (trastuzumab)